Skip to content
MarketScale
‹ Back to IndustriesSciences

Expanding Monitoring in Acute Care and Beyond

This episode is part three of EY's five-part Health and Life Sciences at the Edge series, exploring how hospitals can expand patient monitoring beyond the ICU across the full care continuum. It addresses the challenge of scaling monitoring capabilities without adding alarm fatigue or increased burden for clinicians. The discussion focuses on strategies for smarter, more connected monitoring that supports better patient outcomes.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Michelle Dawn Mooney · Acute CareAi in HealthcareAlarm FatigueAmbient Monitoring
Share

Key takeaways

01

Expanding monitoring beyond the ICU requires balancing broader coverage with clinician workload management.

02

Alarm fatigue remains a critical barrier to effective patient monitoring at scale.

03

This is part of a broader EY series examining the future of health and life sciences at the edge of care.

As hospitals look beyond the ICU to improve outcomes across the entire continuum of care, a key question emerges: how do you expand patient monitoring without overwhelming clinicians with more alarms, more noise, and more work? This episode—part three of a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring—dives into what it will take to make continuous monitoring practical, scalable, and clinically meaningful beyond critical care. Intel’s Andrew Lamkin, AI Solutions Architect, joins Sudha Yellapantula, Senior Researcher at Medical Informatics Corp., in conversation with Michelle Dawn Mooney to unpack how analytics, wearables, and wireless infrastructure are reshaping acute care and beyond.

Yellapantula explains that today’s most advanced monitoring still lives almost exclusively in ICUs, while other hospital areas rely on infrequent spot checks. “If you go to areas where patients are generally more stable… they take a blood pressure once in eight hours,” she notes. That gap creates risk. “There are areas where you could benefit from having more continuous monitoring and you don’t. And then you miss something, and then it’s an emergency.” Expanding monitoring, however, introduces a new challenge: signal overload. Without intelligent filtering, continuous data everywhere quickly becomes noise.

The conversation centers on how analytics must evolve alongside monitoring. “If you put continuous monitoring everywhere, it’s noise,” Yellapantula explains, emphasizing that clinician attention is finite. The goal is not more data, but better prioritization. Strong analytics help zero in on the patients who truly need attention, enabling earlier intervention without burning out care teams. “Clinicians… you can only overload and damage,” she says, reinforcing the need for predictive insights rather than reactive alarms.

Lamkin and Yellapantula also explore what will actually move the needle. While wearables and wireless connectivity are essential, Yellapantula is clear that AI is the differentiator—if the data foundation is strong. “You cannot build AI without good data,” she says, pointing to the joint optimization of sensors, connectivity, and compute. Looking ahead, she envisions a future where AI offloads cognitive burden from clinicians, synthesizing patient history and signals into clear, actionable briefings. “The doctor’s focus should be more focused on the patient,” she explains, with technology accelerating insight rather than adding friction.

As the episode closes, the focus turns toward what’s coming next—from predictive alerts to ambient data capture and clinician-ready dashboards. The message is clear: expanding monitoring isn’t just about placing more sensors. It’s about building intelligent systems that surface the right insight at the right time, helping care teams move from reactive response to proactive care.

Subscribe to this channel on Apple Podcasts and Spotify to hear more from the Intel Internet of Things Group.

About the author

MD

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MD
Michelle Dawn Mooney

Host & Healthcare Content Strategist

Michelle Dawn Mooney is a healthcare media professional and podcast host who covers topics across health, life sciences, and technology. She has hosted and produced content for MarketScale and other B2B media platforms, focusing on clinical innovation and industry trends. Her work spans interviews with executives and clinicians across the healthcare continuum.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512